Were Francis Lo’s ADPT share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were executed under a Rule 10b5-1 trading plan adopted on September 15, 2025, indicating the exercise and sale sequence was pre-arranged rather than timed discretionarily around new company information.

Adaptive Biotechnologies (ADPT) officer sells shares after option exercise

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised stock options and sold shares in a planned transaction. On April 8, 2026, Lo exercised options to acquire 2,344 shares of common stock at $3.99 per share, then sold 22,564 shares of common stock in an open-market sale at a weighted average price of $15.07 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo owns 271,154 shares directly and an additional 2,500 shares indirectly through a spouse.

Insider Trade Summary 10b5-1

Net Seller: 22,564 shares ($340,039)

Net Sell 4 txns

Insider LO FRANCIS

Role Chief People Officer

Sold 22,564 shs ($340K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	2,344	$0.00	--
Exercise	Common Stock	2,344	$3.99	$9K
Sale	Common Stock	22,564	$15.07	$340K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 88,297 shares (Direct); Common Stock — 293,718 shares (Direct); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Key Figures

Options exercised: 2,344 shares Option exercise price: $3.99 per share Shares sold: 22,564 shares +5 more

8 metrics

Options exercised 2,344 shares Stock option exercise on April 8, 2026

Option exercise price $3.99 per share Exercise price for 2,344-share option

Shares sold 22,564 shares Open-market sale on April 8, 2026

Weighted average sale price $15.07 per share Common stock sale price range $14.99–$15.25

Direct holdings after transaction 271,154 shares Common stock directly owned following transactions

Indirect holdings via spouse 2,500 shares Common stock held by spouse, reported as indirect ownership

Options exercised total 2,344 shares ExerciseShares in transaction summary

Net buy/sell shares -22,564 shares NetBuySellShares indicating net sale in summary

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

weighted average price financial

"The price reported for this transaction is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"nature_of_ownership: By You Jin Lee (spouse)"

Form 4 Insider Transactions: What Each Field Means →

04/10/2026 - 06:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LO FRANCIS

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/08/2026		M⁽¹⁾		2,344	A	$3.99	293,718	D
Common Stock	04/08/2026		S⁽¹⁾		22,564	D	$15.07⁽²⁾	271,154	D
Common Stock								2,500	I	By You Jin Lee (spouse)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$3.99	04/08/2026		M⁽¹⁾			2,344	⁽³⁾	03/04/2034	Common Stock	2,344	$0	88,297	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ADPT executive Francis Lo report?

Francis Lo reported exercising options for 2,344 Adaptive Biotechnologies shares at $3.99 each and selling 22,564 common shares at a weighted average price of $15.07 on April 8, 2026, as disclosed in a Form 4 filing.

How many Adaptive Biotechnologies shares did Francis Lo sell?

Francis Lo sold 22,564 shares of Adaptive Biotechnologies common stock. The filing reports a weighted average sale price of $15.07 per share, with individual trades executed between $14.99 and $15.25, according to the detailed pricing footnote.

What option exercise did Francis Lo report for ADPT stock?

Lo exercised a stock option for 2,344 shares of Adaptive Biotechnologies common stock. The option carried an exercise price of $3.99 per share and relates to a grant that vested over time, including monthly vesting following an initial 25% vesting tranche.

How many ADPT shares does Francis Lo hold after these transactions?

After the reported transactions, Francis Lo holds 271,154 Adaptive Biotechnologies common shares directly. The Form 4 also shows 2,500 additional shares held indirectly through Lo’s spouse, identified in the filing as You Jin Lee.

What price range were the ADPT shares sold for in the Form 4?

The Form 4 notes that the reported $15.07 price is a weighted average. Individual sale trades occurred between $14.99 and $15.25 per share, and the insider offers to provide a full breakdown of share counts at each separate sale price upon request.